Cellectis Discusses Recent Arbitral Decision
Cellectis (NASDAQ: CLLS), a pioneering biotechnology company focusing on gene-editing to craft innovative cell and gene therapies, recently shared significant news regarding its arbitration case against Servier. In a formal ruling, the Arbitral Tribunal provided clarity on a dispute concerning an agreement established back in early 2019.
Understanding the Arbitration Outcome
The Tribunal's ruling addressed the License, Development, and Commercialization Agreement that stems from Cellectis and Servier's collaboration. This decision notably includes a partial termination concerning the product UCART19 V1, which is also identified in the market as ALLO-501 by Allogene.
The outcome reflects a pivotal moment for Cellectis. The Tribunal mandated that Cellectis engage in sincere negotiations over the direct licensing of UCART19 V1 to Allogene upon their request. In a sweeping decision, all other claims from the involved parties were dismissed, suggesting a focused resolution on this specific aspect while leaving the rest of their collaboration intact.
Cellectis: Leader in Gene-Editing
As a clinical-stage biotechnology firm, Cellectis is at the forefront of developing revolutionary therapies aimed at transforming cancer treatment. By utilizing a comprehensive allogeneic model for CAR T immunotherapy, the company emphasizes creating off-the-shelf solutions with gene-edited CAR T-cells, enabling efficient treatments for cancer. Their impressive in-house production capabilities allow Cellectis to manage the entire gene therapy development process effectively.
Headquartered in Paris, France, with additional offices in New York and Raleigh, NC, Cellectis holds a dual listing, allowing investors to trade on both the Nasdaq Global Market and Euronext Growth under the tickers CLLS and ALCLS, respectively. This structure not only supports funding but also furthers their ambitious goals in therapeutic innovations.
Future Directions and Growth
Looking ahead, Cellectis plans to capitalize on this ruling by strengthening its engagements while ensuring its innovative therapies continue to progress through various stages of clinical trials. The favorable ruling not only solidifies their approach to genetic therapies but also fortifies partnerships that are crucial in the complex landscape of biotechnology.
By focusing on good-faith negotiations and future collaborations, Cellectis aims to position itself even more strongly within the competitive market of advanced cancer treatments. With a pipeline steeped in cellular innovations, the company is poised for substantial growth.
Contact Information for Cellectis
To keep up with Cellectis's developments, interested parties can visit their official website for detailed updates. For specific inquiries, media relations can be directed to Pascalyne Wilson, the Communications Director, or Patricia Sosa Navarro, Chief of Staff to the CEO. Investor relations are managed by Arthur Stril, who is positioned to provide strategic insights into the company's financial direction.
Frequently Asked Questions
What was the main outcome of the arbitration ruling?
The Tribunal ruled for a partial termination of the License Agreement regarding product UCART19 V1 and mandated good-faith discussions about direct licensing with Allogene.
What does Cellectis specialize in?
Cellectis specializes in gene-editing technologies, developing cell and gene therapies focusing on cancer treatment through innovative CAR T immunotherapy.
Where is Cellectis headquartered?
Cellectis is headquartered in Paris, France, with additional offices located in New York and Raleigh, NC.
What are Cellectis's stock tickers?
Cellectis trades on the Nasdaq under the ticker CLLS and on Euronext Growth as ALCLS.
Who can I contact for more information about Cellectis?
For media inquiries, contact Pascalyne Wilson or Patricia Sosa Navarro, while investor inquiries can be directed to Arthur Stril.
